

Review article

***Corynebacterium pseudotuberculosis*: microbiology, biochemical properties, pathogenesis and molecular studies of virulence**

Fernanda Alves DORELLA<sup>a</sup>, Luis Gustavo Carvalho PACHECO<sup>a</sup>,  
Sergio Costa OLIVEIRA<sup>b</sup>, Anderson MIYOSHI<sup>a</sup>, Vasco AZEVEDO<sup>a\*</sup>

<sup>a</sup> Laboratório de Genética Celular e Molecular, Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, CP 486, CEP 31270-901, Belo Horizonte, MG, Brazil

<sup>b</sup> Laboratório de Imunologia de Doenças Infecciosas, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, CP 486, CEP 31270-901, Belo Horizonte, MG, Brazil

(Received 2 February 2005; accepted 4 November 2005)

**Abstract** – *Corynebacterium pseudotuberculosis* is the etiological agent of caseous lymphadenitis (CLA), a common disease in small ruminant populations throughout the world. Once established, this disease is difficult to eradicate because drug therapy is not effective and because the clinical detection of infected animals is of limited efficiency. We reviewed the microbiological, biochemical and taxonomic features of *C. pseudotuberculosis*, general aspects of infection, the main virulence determinants and currently available commercial vaccines. We also examined the current molecular strategies for the study of virulence in *C. pseudotuberculosis*, including the latest research on the identification of novel virulence factors and genes, which will help us to better understand the biology of this microorganism. This knowledge may also contribute to the development of improved CLA vaccines, including subunit and DNA-based types, as well as to improve the diagnosis, treatment and control of this disease.

***Corynebacterium pseudotuberculosis* / caseous lymphadenitis / pathogenesis / virulence / vaccine**

**Table of contents**

1. Introduction .....	
2. Microbiological, biochemical and taxonomic features of <i>C. pseudotuberculosis</i> .....	
2.1. Microbiological aspects .....	
2.2. Biochemical properties .....	
2.3. Antimicrobial susceptibility .....	
2.4. Taxonomy .....	
3. General aspects of <i>C. pseudotuberculosis</i> infection .....	
3.1. Transmission .....	
3.2. Human cases .....	
3.3. Caseous lymphadenitis .....	

---

\* Corresponding author: vasco@icb.ufmg.br

3.4. Epidemiology of CLA .....	
3.5. Diagnosis and control of CLA .....	
4. From proteins to DNA: Commercial and experimental vaccines .....	
4.1. Commercial vaccines .....	
4.2. Experimental vaccines .....	
5. Determinants of virulence .....	
5.1. Phospholipase D .....	
5.2. Toxic cell-wall lipids .....	
5.3. New candidates .....	
6. Molecular strategies for the study of virulence in <i>C. Pseudotuberculosis</i> .....	
6.1. Identification of immunodominant peptides .....	
6.2. Generation of mutants .....	
7. Future directions .....	

## 1. INTRODUCTION

The genus *Corynebacterium* belongs to a suprageneric group of actinomycetes that also includes the genera *Mycobacterium*, *Nocardia* and *Rhodococcus* [46, 87, 100, 102]. These gram-positive bacteria (*Corynebacterium*, *Mycobacterium*, *Nocardia* and *Rhodococcus* species), termed the CMN group, constitute a very heterogeneous group; however, most of the species share particular characteristics, such as: (i) a specific cell wall organization, mainly characterized by the presence of a huge polymer complex composed of peptidoglycan, arabinogalactan and mycolic acids [5, 26–28, 39, 45, 48] and (ii) high G+C content (47–74%) [39, 40, 43, 80]. The genomes of several species of this group have already been completely sequenced; this fact reflects the considerable medical, veterinary and biotechnological importance of these organisms (Tab. I).

*Corynebacterium pseudotuberculosis* is an important animal pathogen. It is the etiological agent of a disease that is commonly called caseous lymphadenitis (CLA) or cheesy gland [114]. This disease is found in all the world's major sheep and goat production areas, causing significant economic losses [85, 114].

In this review, we present the main microbiological characteristics of *C. pseudotuberculosis*. Bacterial virulence determinants, including previously reported vir-

ulence factors and recently identified molecules, are discussed, with emphasis on the molecular strategies that have been used to identify and study such determinants. The aspects regarding CLA are also covered, focusing on the currently-available commercial and experimental vaccines.

## 2. MICROBIOLOGICAL, BIOCHEMICAL AND TAXONOMIC FEATURES OF *C. PSEUDOTUBERCULOSIS*

### 2.1. Microbiological aspects

*Corynebacterium pseudotuberculosis* was isolated from bovine farcy in 1888 by Nocard. Preisz, in 1894, was the first to completely describe this microorganism and to observe its resemblance to the diphtheria bacillus. Synonyms for *C. pseudotuberculosis* were *Bacillus pseudotuberculosis ovis*, *Bacillus pseudotuberculosis*, *Corynebacterium ovis* and Preisz-Nocard bacillus [59, 72].

This microorganism is a facultative intracellular pathogen that exhibits pleomorphic forms, such as coccoids and filamentous rods, ranging in size from 0.5  $\mu\text{m}$  to 0.6  $\mu\text{m}$  by 1.0  $\mu\text{m}$  to 3.0  $\mu\text{m}$  [17, 28, 72, 97]. It is a non-sporulating, non-capsulated and non-motile bacterium; however, it has fimbriae [17, 46, 72]. This bacterium is a

**Table 1.** The main representatives of the CMN group.

Representative	Status	Importance	Sequenced strain	Genome size (Mbp)	GC contents (%)	Reference
<i>Corynebacterium diphtheriae</i>	Complete	Causal agent of the disease diphtheria in humans	NCTC 13129	2.488	53	[20]
<i>Corynebacterium efficiens</i>	Complete	Production of glutamate and other amino acids and compounds	YS-314	3.147	63	[81]
<i>Corynebacterium glutamicum</i>	Complete	Production of glutamate, other amino acids (L-lysine) and compounds	ATCC 13032	3.309	53	[55]
<i>Mycobacterium avium</i>	In progress	Causes tuberculosis in birds and disseminated infections in immunocompromized humans (the elderly, children, and especially patients with AIDS)	104	5.480	68	<a href="http://www.tigr.org/db/mdb/mdbinprogress.html">http://www.tigr.org/db/mdb/mdbinprogress.html</a>
<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i>	Complete	Causative agent of Johne's disease, or paratuberculosis, a chronic severe intestinal infection. The disease affects domestic and free-ranging ruminants, but has also been reported in primates, rabbits, stoats and foxes	k10	4.829	69	[88]
<i>Mycobacterium bovis</i>	Complete	Causative agent of classic bovine tuberculosis, but it can also cause the disease in humans, especially if contaminated milk is consumed without prior pasteurization. This is a fully virulent strain	AF2122/97	4.345	65	<a href="http://www.sanger.ac.uk/Projects/M_bovis/">http://www.sanger.ac.uk/Projects/M_bovis/</a> [41]
<i>Mycobacterium bovis</i>	In progress	Causative agent of classic bovine tuberculosis, but it can also cause the disease in humans. This is the strain that is used to produce BCG (Bacille de Calmette et Guèrin) vaccine, a well-known tuberculosis vaccine	BCG	4.400	57	<a href="http://www.pasteur.fr/recherche/unites/Lgmb/mycogenomics.htm">http://www.pasteur.fr/recherche/unites/Lgmb/mycogenomics.htm</a>
<i>Mycobacterium leprae</i>	Complete	Causative agent of human leprosy	TN	3.268	57	[38]
<i>Mycobacterium smegmatis</i>	In progress	Generally non-pathogenic mycobacterium capable of causing soft tissue lesions. This bacterium was initially isolated from human smegma. It is associated with soft tissue lesions following trauma or surgery	MC2 155	7.040	57	<a href="http://www.tigr.org/db/mdb/mdbinprogress.html">http://www.tigr.org/db/mdb/mdbinprogress.html</a>

**Table I.** Continued.

Representative	Status	Importance	Sequenced strain	Genome size (Mbp)	GC contents (%)	Reference
<i>Mycobacterium tuberculosis</i>	Complete	Causative agent of tuberculosis. It is highly contagious, infecting approximately 80% of the patient's social contacts	CDC1551	4.403	65	[36]
<i>Mycobacterium tuberculosis</i>	Complete	Causative agent of tuberculosis. Unlike some clinical isolates, it retains full virulence in animal models of tuberculosis and is susceptible to drugs and receptive to genetic manipulation	H37Rv	4.411	65	[25]
<i>Mycobacterium tuberculosis</i>	In progress	Causative agent of tuberculosis. It was subsequently found that this strain is one of the most wide-spread and virulent <i>Mycobacterium tuberculosis</i> strains	210	4.400	57	<a href="http://www.tigr.org/db/mdb/mdbinprogress.html">http://www.tigr.org/db/mdb/mdbinprogress.html</a>
<i>Nocardia farcinica</i>	Complete	The causative agent of nocardiosis, affecting the lung, central nervous system, and cutaneous tissues of humans and animals. This species exhibits a greater degree of virulence than the more common <i>Nocardia asteroides</i>	IFM 10152	6.021 (Chromosome) 0.184 (Plasmid pNF1) 0.087 (Plasmid pNF2)	70 67 68	[56]
<i>Rhodococcus</i> sp.	In progress	Microbe capable of degrading a wide variety of polychlorinated biphenyls	RHA1	9,700		<a href="http://www.rhodococcus.ca">http://www.rhodococcus.ca</a>

facultative anaerobe and grows best at 37 °C, at a pH of 7.0 to 7.2 [17, 72, 97]. It grows sparse initially on the agar surface and then becomes organized in clumps or in palisades, taking on a cream to orange coloration; colonies are dry, opaque and concentrically ringed. Growth in fluid medium develops as a granular deposit with a surface pellicle [17, 72, 77]. Haemolysis on blood agar is variable, but large zones develop in the presence of *Rhodococcus equi* [17]. *Corynebacterium pseudotuberculosis* toxin inhibits the action of staphylococcal  $\beta$ -lysin [59].

*Corynebacterium pseudotuberculosis* stains Gram-positive and when stained by Albert's or Neisser's method, volutin granules can be visualized. These metachromatic granules are clearly observed in the bacillary form, but are absent from coccoid cells; they contain high-energy phosphate reserves [46, 72].

## 2.2. Biochemical properties

Cell wall peptidoglycan is based on meso-diaminopimelic acid (*meso*-DAP). Arabinose and galactose are major cell wall sugars. Short-chain mycolic acids (corynomycolic acids, 22–36 carbon atoms) are present [59, 94, 97]. Biochemical reactions of *C. pseudotuberculosis* isolates vary considerably, mainly in their fermenting ability [72, 100, 105]. All strains produce acid, but not gas, from many carbon sources, including glucose, fructose, maltose, mannose, and sucrose [17, 53, 59, 72]. This bacterium is phospholipase D and catalase positive, oxidase negative, and it is beta-hemolytic [59, 77, 100]. Strains isolated from small ruminants generally do not reduce nitrate [17, 72, 100, 114].

A well-established biochemical test for coryneform bacteria identification is the API Coryne system (API-bioMérieux, Inc., La Balme les Grottes, France). This method consists of 21 biochemical tests; it can be performed in 24–48 h. The test contains 20 tubes containing substrates that allow

for 11 enzyme tests (pyrazinamidase, pyrrolidonyl arylamidase,  $\beta$ -galactosidase, alkaline phosphatase,  $\alpha$ -glucosidase, *N*-acetylglucosaminidase,  $\beta$ -glucuronidase, and nitrate reduction and gelatin, urea and esculin hydrolysis) and eight carbohydrate fermentation tests (glucose, ribose, D-xylose, mannitol, maltose, lactose, sucrose and glycerol). This system is more reliable and rapid when it is compared with standard identification methods (API-bioMérieux, Inc.). A summary of general biochemical properties of *C. pseudotuberculosis* is presented in Table II.

## 2.3. Antimicrobial susceptibility

The susceptibility pattern of *C. pseudotuberculosis* to antimicrobial agents varies among isolates obtained from various sources [28, 37, 66]. Muckle and Gyles [77], in a study of 26 strains isolated from lesions of caseous lymphadenitis in goats, reported that all strains were susceptible to the antibiotics ampicillin, chloramphenicol, lincomycin, gentamicin, tetracycline, penicillin G and sulfamethoxazole-trimethoprim. Only three isolates were susceptible to neomycin, and all strains were resistant to streptomycin. Garg et al. [40] reported strains of *C. pseudotuberculosis* that were strongly resistant to penicillin but susceptible to neomycin. A strain highly resistant to streptomycin (500  $\mu$ g/mL) was observed in a study of 22 isolates of *C. pseudotuberculosis* from sheep and goat abscesses [90]. Minimal inhibitory concentration (MIC) values for all isolates were similar for the various antimicrobial agents. Later studies also indicated a similarity of MIC values among strains [1, 29, 60]. However, Fernández et al. [35] found higher MIC values for several antimicrobial agents, in an analysis of corynebacteria isolated from ewe mastitis.

Olson et al. [82] grew *C. pseudotuberculosis* as a biofilm, in an attempt to reproduce the environment of a natural infection. They observed that this bacterium was

**Table II.** Biochemical characteristics of *Corynebacterium pseudotuberculosis*.

Biochemical characteristics			
Acid production		Hydrolysis	
Glucose	+	Esculin	–
Arabinose	d	Hippurate	–
Xylose	–	Urea	+
Rhamnose	–	Tyrosine	–
Fructose	+	Casein	–
Galactose	+		
Mannose	+	Phosphatase	+
Lactose	–	Pyrazinamidase	–
Maltose	+	Methyl red	+
Sucrose	d	Nitrate reduction	d
Trehalose	–	Catalase	+
Raffinose	–	Oxidase	–
Salicin	–	Lipophilism	–
Dextrin	d		
Starch	–		

+ more than 90% are positive: d 21–89% are positive: – more than 90% are negative or resistant.

highly resistant to all the drugs that they tested under such growth conditions.

#### 2.4. Taxonomy

Classification of *C. pseudotuberculosis* was originally based on morphological and biochemical characteristics [59, 77]. Nitrate reductase production was used by Biberstein et al. [8] to distinguish the *equi* biovar (isolated from horses and cattle; nitrate reduction positive) from the *ovis* biovar (isolated from sheep and goats; nitrate reduction negative). Later, Songer et al. [100] reached the same conclusion using restriction endonuclease (*EcoRV* and *PstI*) analyses of chromosomal DNA, and based on nitrate reduction data. More recently, the same result was also observed with restriction fragment length polymorphisms of 16S-rDNA [29, 105, 111]. Connor et al. [28] used pulsed-field gel electrophoresis, associated with biochemical analysis, for the characterization of *C. pseudotuberculosis* isolates.

A close relationship between *C. pseudotuberculosis* and *C. ulcerans* was suggested by the fact that these organisms are unique among the corynebacteria in producing phospholipase D [15, 44]. Moreover, some strains of *C. ulcerans* and *C. pseudotuberculosis* can produce diphtheria toxin (DT). Furthermore, some non-toxigenic strains are converted to toxigeny (DT production) by  $\beta$ -phages from toxigenic *C. diphtheriae* [15, 23, 24, 44].

Molecular methods, including nucleic acid hybridization and 16S rRNA gene sequence analysis, have been used to determine the degree of relatedness of many different corynebacterial species and strains [54, 62, 95, 107]. Riegel et al. [95] found that some strains of *C. pseudotuberculosis* and *C. ulcerans* belong to a monophyletic group, based on phylogenetic analysis of small-subunit rDNA sequences that are only found in the CMN group. They also concluded that the *equi* and *ovis* biovars of *C. pseudotuberculosis* should not be classified

as subspecies, due to their high genomic similarity. In two other independent studies [54, 107], *C. pseudotuberculosis* was found to be closely related to *C. ulcerans*.

More recently, analysis of partial gene sequences from the  $\beta$ -subunit of RNA polymerase (*rpoB*) has been shown to be more accurate for the identification of *Corynebacterium* species than analyses based on 16S rDNA [61, 62]. This method has also been successfully used to identify mycobacterial species [63]. Although the *rpoB* gene is a powerful identification tool, many authors propose that it may be used to complement the 16S rRNA gene analysis in the phylogenetic studies of *Corynebacterium* and *Mycobacterium* species [61–63, 74]. We have constructed a phylogenetic tree based on *rpoB* gene sequences of reference strains from the CMN group (Fig. 1). Based on this phylogenetic tree, we can observe a clear relationship between *C. pseudotuberculosis* and *C. ulcerans*. Moreover, analysis using the *rpoB* gene allowed the identification of the group that these two species belong to, as previously observed [61, 62].

### 3. GENERAL ASPECTS OF *C. PSEUDOTUBERCULOSIS* INFECTION

Though *C. pseudotuberculosis* was originally identified as the causative microorganism of CLA in sheep and goats, this bacterium has also been isolated from other species, including horses, in which it causes ulcerative lymphangitis and pigeon fever in cattle, camels, swine, buffaloes, and humans [89, 97, 114, 117].

#### 3.1. Transmission

The potential of *C. pseudotuberculosis* to survive for several weeks in the environment likely contributes to its ability to spread within a herd or flock [4, 117]. Transmission among sheep or goats occurs mainly through contamination of superfi-

cial wounds, which can appear during common procedures, such as shearing, castration and ear tagging, or through injuries of the animal's bodies generated by other traumatic events. Not infrequently, contaminated sheep cough bacteria onto skin cuts of other sheep, constituting another means of transmission [84, 114]. In cattle, as well as in buffaloes, there is evidence of mechanical transmission of this bacterium by houseflies and by other Diptera, though the natural mechanisms of infection with *C. pseudotuberculosis* are not well documented [97, 116, 117].

#### 3.2. Human cases


Human infection caused by *C. pseudotuberculosis* is a rare event, and most of the reported cases have been related to occupational exposure; one case, diagnosed in 1988, involved the ingestion of raw goat meat and cow milk [89]. About 25 cases of infection of humans with this microorganism have been reported in the literature [67, 73, 89].

Peel et al. [89] reviewed 22 cases, in which infected humans were generally presented with lymphadenitis, abscesses, and constitutional symptoms. Mills et al. [73] described suppurative granulomatous lymphadenitis in a boy, due to contact with contaminated farm animals. Liu et al. [67] reported a *C. pseudotuberculosis* infection in a patient's eye, due to an ocular implant.

In most cases, the patients received antibiotic therapy and the affected lymph nodes were surgically removed [67, 73, 89].

#### 3.3. Caseous lymphadenitis

Caseous lymphadenitis causes significant economic losses to sheep and goat producers worldwide, mainly due to the reduction of wool, meat and milk yields, decreased reproductive efficiencies of affected animals and condemnation of carcasses and skins in abattoirs [3, 83]. The manifestations of CLA in small ruminants are characterized



**Figure 1.** Dendrogram representing the phylogenetic relationships of the CMN group (*Corynebacterium*, *Mycobacterium*, *Nocardia* and *Rhodococcus* species) obtained by the neighbor-joining method [96]. The tree was derived from the alignments of *rpoB* gene sequences. The phylogenetic distances were calculated by the software MEGA 3 [64]. The support of each branch, as determined from 1 000 bootstrap samples, is indicated by the value at each node (in percent).

mainly by bacteria-induced caseation necrosis of the lymph glands. The most frequent form of the disease, external CLA, is characterized by abscess formation in superficial lymph nodes and in subcutaneous tissues. These abscesses can also develop internally in organs, such as the lungs, kidneys, liver and spleen, characterizing visceral CLA [72, 91]. In some cases, the infection produces few obvious clinical signs in the animal, remaining unrecognized until a post-mortem examination has been carried out, making it difficult to obtain definitive data about the prevalence of this disease [3, 17, 83].

### 3.4. Epidemiology of CLA

Recent epidemiological surveys have examined the prevalence of CLA in different countries [2, 3, 6, 11, 28, 85]. Among flocks surveyed in Australia, the average prevalence of CLA in adult sheep was 26% [85]. Forty-five percent of the farmers interviewed in a study in the United Kingdom had seen abscesses in their sheep; however, this could be an overestimation of CLA prevalence since few farmers had investigated the causes of the abscesses [11]. Twenty-one percent of 485 culled sheep examined in Canadian slaughterhouses had CLA [3]. This disease remains an important subject of veterinary concern throughout the world.

### 3.5. Diagnosis and control of CLA

Controlling CLA with antibiotics is not an easy task, since viable bacteria stay protected inside abscesses due to the thick capsule that surrounds them [91, 103, 114]. It is generally agreed that the best strategy to control the disease is vaccination of healthy animals, along with the identification/removal of infected animals [13, 71, 84, 114]. However, the difficulties associated with the early clinical identification of infected animals can be a hindrance to such a strategy.

Several serodiagnostic tests have been developed to overcome the problem of clinical identification of CLA, but most have been reported to lack either sensitivity or specificity [14, 16, 70, 71, 104, 114, 118]. Nevertheless, some enzyme-linked immunosorbent assay (ELISA)-based diagnostic tests have been reported to be effective in control and eradication programs [32, 33, 110]. Recently, ELISA tests to detect gamma interferon (IFN- $\gamma$ ), as a marker of cell-mediated immunity against *C. pseudotuberculosis*, have been developed [71, 86, 93]. The IFN- $\gamma$  ELISA test appears to be more sensitive than the normal antibody ELISA in detecting prior infection in goats, and it does not seem to be affected by vaccination in sheep [71]. Another novel strategy that holds promise for the diagnosis of CLA is the use of polymerase chain reaction (PCR) tests specific for *C. pseudotuberculosis* to identify bacteria isolated from abscesses [21].

## 4. FROM PROTEINS TO DNA: COMMERCIAL AND EXPERIMENTAL VACCINES

### 4.1. Commercial vaccines

Most of the currently-available commercial vaccines for caseous lymphadenitis are combined with vaccines against other pathogens. These include *Clostridium tetani*, *Cl. perfringens*, *Cl. septicum*, *Cl. novyi* and *Cl. chauvoei* [85, 91, 103, 114]. These vaccines are based on inactivated phospholipase D (PLD) and are called toxoid vaccines.

Paton et al. [84], in an analysis of the effectiveness of a combined toxoid vaccine against CLA, reported a reduction in the number and size of CLA lung abscesses and a decrease in the spread of this disease within the flock. However, in another study [85], it was reported that although 43% of the farmers applied commercial CLA vaccines, only 12% used them correctly. It was concluded that adjustments in vaccination

programs would dramatically diminish the prevalence of CLA.

Not all the vaccines licensed for use in sheep can be used to vaccinate goats. Moreover, while the recommended vaccination program for sheep consists of two priming doses in lambs and yearly boosters in adult sheep, revaccination is recommended at six-month intervals in goats [85, 114].

A live attenuated vaccine strain of *C. pseudotuberculosis*, strain 1002, has been licensed for use in Brazil since 2000. It is already being produced industrially and is available in a liquid form that must be administered yearly to the animals, subcutaneously; a lyophilized version is also being developed by the Empresa Baiana de Desenvolvimento Agrícola (<http://www.ebda.ba.gov.br>). This live vaccine was reported to confer around 83% protection against CLA in goats in experimental assays and in field trials.

#### 4.2. Experimental vaccines

*Corynebacterium pseudotuberculosis* Toxminus (pld mutant) has been used as a live bacterial vector to deliver heterologous antigenic proteins [75]. Five heterologous genes (the gene coding for *Mycobacterium leprae* 18-kDa antigen, *Taenia ovis* 45W gene, *Babesia bovis* 11C5 antigen, the *Dichelobacter nodosus* gene encoding mature basic protease (*bprV*) and *Anaplasma marginale* ApH antigen), plus a genetically inactivated analogue of PLD, were used to construct plasmids expressing foreign genes in the Toxminus strain. Three proteins elicited specific antibody responses in experimentally vaccinated sheep. The expression by Toxminus of mature basic protease (*bprV*) of *D. nodosus* fused to the carboxy-terminus of *Mycobacterium leprae* 18-kDa antigen against ovine footrot [76] was also tested. Though the animals were not protected from footrot, this live recombinant vaccine was capable of eliciting a humoral immune response, and it may be capable of successfully delivering a foreign antigen.

Recently, the immune responses of sheep vaccinated with a DNA vaccine expressing the extracellular domain of bovine CTLA-4, fused to HIg and a genetically detoxified phospholipase D (boCTLA-4-HIg-PLD) from *C. pseudotuberculosis* have been investigated [22]. CTLA-4 binds with high affinity to the B7 membrane antigen on antigen-presenting cells (APC), enhancing the humoral immune response to a vaccine antigen. Though the genetically attenuated vaccine was found to be only partially effective against experimental challenge with *C. pseudotuberculosis*, the targeted DNA vaccine provided sheep with a significantly improved antibody response. In order to improve the efficacy of this DNA vaccine, De Rose et al. [31] tested different routes of immunization: (i) intramuscular DNA injection, (ii) subcutaneous DNA injection and (iii) gene gun bombardment. Intramuscular vaccination gave a level of protection similar to that observed with protein vaccination, while subcutaneous and gene gun vaccination did not protect sheep against bacterial challenge.

## 5. DETERMINANTS OF VIRULENCE

### 5.1. Phospholipase D

Phospholipase D (PLD) is a potent exotoxin produced by *C. pseudotuberculosis* and it has been considered as the major virulence factor for this bacterium [51, 65].

This exotoxin is a permeability factor that promotes the hydrolysis of ester bonds in sphingomyelin in mammalian cell membranes, possibly contributing to the spread of the bacteria from the initial site of infection to secondary sites within the host [19, 30, 65, 69, 89, 106, 108]. Moreover, it provokes dermonecrotic lesions, and at higher doses it is lethal to a number of different species of laboratory and domestic animals [34, 102]. Damage and destruction of caprine macrophages have been observed during infection with *C. pseudotuberculosis*.

This lethal effect is due to action of PLD [109].

Several of the biological activities of *C. pseudotuberculosis* PLD, as well as its molecular structure, have also been found in sphingomyelinases in the venom of the medically important spider genus *Loxosceles* [7, 10, 30, 102, 108, 112].

The use of an antitoxin has prevented the spread of *C. pseudotuberculosis* within the host; however, it is not able to prevent the development of abscesses [114]. Moreover, vaccination of goats with formalized exotoxin, i.e. with inactive PLD, also prevented the spread of bacteria, following experimental challenge [13].

### 5.2. Toxic cell-wall lipids

The surface lipids of *C. pseudotuberculosis* have long been described as major factors contributing to its pathogenesis [18, 47, 48, 58]. The toxicity of the extracted lipid material has been demonstrated by the induction of hemorrhagic necrosis following intradermal injection in guinea pigs [58]. Mouse peritoneal macrophages were found to be highly susceptible to the necrotizing action of *C. pseudotuberculosis* surface lipids, but this cytotoxic effect is not observed in rabbit cells [48]. However, infection with *C. pseudotuberculosis* in the guinea pig invariably progresses until death, while guinea pig macrophages are not susceptible to the cytotoxic action of the bacterial lipids [48, 57]. Tashjian et al. [109] observed that *C. pseudotuberculosis* was resistant to killing and digestion by caprine macrophages due to its lipid coat.

A study carried out in mice with 25 isolates of *C. pseudotuberculosis* proposed that there is a direct relationship of the percentage of surface lipids with the induction of chronic abscessation [78].

### 5.3. New candidates

Recently, it has been proposed that a putative *C. pseudotuberculosis* iron uptake

gene cluster has a role in its virulence [9]. The four genes in this putative operon were identified downstream from the *pld* gene. They were designated as Fe acquisition genes (*fag*) *A*, *B*, *C* and *D*. Since *C. pseudotuberculosis* is an intracellular pathogen, this bacterium must be able to acquire iron from an environment in which this nutrient is scarce. Although there was no alteration in the utilization of iron by a *fagB(C)* mutant in vitro, this mutant had a decreased ability to survive and to cause abscesses in experimentally-infected goats [9].

## 6. MOLECULAR STRATEGIES FOR THE STUDY OF VIRULENCE IN *C. PSEUDOTUBERCULOSIS*

### 6.1. Identification of immunodominant peptides

To date, the most widely studied *C. pseudotuberculosis* protein is PLD. It has already been purified, cloned and expressed in *E. coli* [34, 50, 69, 101].

A protective antigen, corynebacterial secreted protease 40 (CP40) [115], has been identified in *C. pseudotuberculosis* by applying a strategy that involves the local immune response, analyzing the specificity of antibodies produced by B cells [113]. Antibody secreting cells (ASC), obtained from induced infections in sheep, produce antibodies with high specificity. These antibodies are used as probes to screen whole-cell antigens of *C. pseudotuberculosis* by immunoblots. CP40 was one of the earliest antigens recognized in immunoblots of sera. ELISA tests confirmed the results obtained with immunoblots, and field trials with this semipurified antigen showed that CP40 was highly protective against experimentally-induced CLA [113].

Some researchers have analyzed and characterized soluble and insoluble proteins that have immunodominant potential [12, 79]. Though many other immunogenic excreted-secreted components have been

described, using immunoblot techniques [86, 87], these proteins have not been identified. However, they reliably detected CLA infection in goats, and they could be used as vaccine components.

## 6.2. Generation of mutants

Random chemical mutagenesis, with formic acid, was used by Haynes et al. [49] to produce enzymatically-inactive PLD. This analog protein, though inactive, still had immunological activity [49]. Hodgson et al. [51] and McNamara et al. [68] used site-specific mutagenesis to produce *pld* mutants that had reduced ability to establish infection and were unable to disseminate in sheep and goats.

Site-specific amino acid substitution has also been used to generate genetic inactivation of the *pld* gene in two independent experiments. Tachedjian et al. [106] substituted the His20 in the PLD active site with other amino acids, obtaining mutants that were able to produce a genetically-inactivated version of PLD. After analysis of mutant gene expression, two mutants were selected that retained features useful for toxoid vaccine development. In another study, the inactivated protein, in which His20 was substituted by Ser, gave 44% protection in sheep challenged with the bacterium [52].

A mutant of the *C. pseudotuberculosis* *recA* gene was generated by site-specific inactivation [92]. The mutant had its homologous recombination efficiency decreased 8–10 fold. Nevertheless, *in vivo* analysis revealed that the mutated *recA* gene did not affect the virulence of this bacterium in mice.

Reduction of virulence of *C. pseudotuberculosis* mutants was obtained by Simmons et al. [98]. Allelic exchange was used to generate *aroQ*-attenuated mutants that were unable to cause CLA in murine models. It was suggested that highly attenuated

*aroQ* mutants of *C. pseudotuberculosis* could be used as vaccine vectors [99].

The ability of the *fag* genes to be induced by limited iron was studied by transcriptional fusions with the *lacZ* reporter gene, followed by an assay for  $\beta$ -galactosidase activity [9]. The resultant mutants were grown in both iron-rich and iron-limited media. The mutants expressed very low levels of  $\beta$ -galactosidase activity in iron-rich medium and almost three-fold more in iron-limited medium. Although not well expressed *in vitro*, this putative operon appears to be induced by limited iron.

Our research group has identified 34 insertional mutants of genes coding for fimbrial and transport subunits, and also for hypothetical and unknown function proteins from *C. pseudotuberculosis*, using random transposon mutagenesis with the TnFuZ transposition system [42], a tool that generates transcriptional and translational fusions with the *phoZ* gene (encoding alkaline phosphatase) of *Enterococcus faecalis*<sup>1</sup>. This discovery indicates promising target genes that could contribute to the development of attenuated vaccine strains.

## 7. FUTURE DIRECTIONS

Despite the various molecular strategies that have been employed, efficient tools for the genetic study of *C. pseudotuberculosis* are still scarce. In fact, the main reason for the lack of molecular investigation of this organism is that the genetics of the genus have been little studied with modern techniques, making it difficult to identify and characterize factors that could be involved in virulence [20]. Nevertheless, other representatives of the CMN group are better characterized, and the genetic tools that have been developed could be directly applicable to *C. pseudotuberculosis* in future studies.

---

<sup>1</sup> Dorella F.A., Estevam E.M., Pacheco L.G.C., Guimarães C.T., Lana U.G.P., Gomes E.A., Miyoshi A., Azevedo V., unpublished results.

## ACKNOWLEDGEMENTS

Miyoshi A. and Azevedo V. share the same credit in the senior authorship of this work. This work was supported by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brasil), CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brasil), FINEP (Financiadora de Estudos e Projetos- 01.04.760.00) and FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Brasil).

## REFERENCES

- [1] Adamson P.J., Wilson W.D., Hirsh D.C., Baggot J.D., Martin L.D., Susceptibility of equine bacterial isolates to antimicrobial agents, *Am. J. Vet. Res.* 46 (1985) 447–450.
- [2] Al-Rawashdeh O.F., al-Qudah K.M., Effect of shearing on the incidence of caseous lymphadenitis in Awassi sheep in Jordan, *J. Vet. Med. B Infect. Dis. Vet. Public Health* 47 (2000) 287–293.
- [3] Arsenaault J., Girard C., Dubreuil P., Daignault D., Galarneau J.-R., Boisclair J., Simard C., Bélanger D., Prevalence of and carcass condemnation from maedi-visna, paratuberculosis and caseous lymphadenitis in culled sheep from Quebec, Canada, *Prev. Vet. Med.* 59 (2003) 67–81.
- [4] Augustine J.L., Renshaw H.W., Survival of *Corynebacterium pseudotuberculosis* in axenic purulent exudate on common barnyard fomites, *Am. J. Vet. Res.* 47 (1986) 713–715.
- [5] Bayan N., Houssin C., Chami M., Leblon G., Mycomembrane and S-layer: two important structures of *Corynebacterium glutamicum* cell envelope with promising biotechnology applications, *J. Biotechnol.* 104 (2003) 55–56.
- [6] Ben Said M.S., Ben Maitigue H., Benzarti M., Messadi L., Rejeb A., Amara A., Epidemiological and clinical studies of ovine caseous lymphadenitis, *Arch. Inst. Pasteur Tunis* 79 (2002) 51–57.
- [7] Bernheimer A.W., Campbell B.J., Forrester L.J., Comparative toxinology of *Loxosceles reclusa* and *Corynebacterium pseudotuberculosis*, *Science* 228 (1985) 590–591.
- [8] Biberstein E.L., Knight H.D., Jang S., Two biotypes of *Corynebacterium pseudotuberculosis*, *Vet. Rec.* 89 (1971) 691–692.
- [9] Billington S.J., Esmay P.A., Songer J.G., Jost B.H., Identification and role in virulence of putative iron acquisition genes from *Corynebacterium pseudotuberculosis*, *FEMS Microbiol. Lett.* 208 (2002) 41–45.
- [10] Binford G.J., Cordes M.H.J., Wells M.A., Sphingomyelinase D from venoms of *Loxosceles* spiders: evolutionary insights from cDNA sequences and gene structure, *Toxicon* 45 (2005) 547–560.
- [11] Binns S.H., Bairley M., Green L.E., Postal survey of ovine caseous lymphadenitis in the United Kingdom between 1990 and 1999, *Vet. Rec.* 150 (2002) 263–268.
- [12] Braithwaite C.E., Smith E.E., Songer J.G., Reine A.H., Characterization of detergent-soluble proteins of *Corynebacterium pseudotuberculosis*, *Vet. Microbiol.* 38 (1993) 59–70.
- [13] Brown C.C., Olander H.J., Biberstein E.L., Morse S.M., Use of a toxoid vaccine to protect goats against intradermal challenge exposure to *Corynebacterium pseudotuberculosis*, *Am. J. Vet. Res.* 47 (1986) 1116–1119.
- [14] Brown C.C., Olander H.J., Alves S.F., Synergistic hemolysis-inhibition titers associated with caseous lymphadenitis in a slaughterhouse survey of goats and sheep in Northeastern Brazil, *Can. J. Vet. Res.* 51 (1987) 46–49.
- [15] Buck G.A., Cross R.E., Wong T.P., Loera J., Groman N., DNA relationships among some *tox*-bearing corynebacteriophages, *Infect. Immun.* 49 (1985) 679–684.
- [16] Burrell D.H., A simplified double immunodiffusion technique for detection of *Corynebacterium ovis* antitoxin, *Res. Vet. Sci.* 28 (1980) 234–237.
- [17] Buxton A., Fraser G., *Corynebacterium*, in: Buxton A., Fraser G. (Eds.), *Animal Microbiology*, Blackwell Scientific Publications, Edinburgh, 1977, pp. 177–183.
- [18] Carne H.R., Kater J.C., Wickham N., A toxic lipid from the surface of *Corynebacterium ovis*, *Nature* 178 (1956) 701–702.
- [19] Carne H.R., Onon E.O., Action of *Corynebacterium ovis* exotoxin on endothelial cells of blood vessels, *Nature* 271 (1978) 246–248.
- [20] Cerdeño-Tárraga A.M., Efstratiou A., Dover L.G., Holden M.T.G., Pallen M., Bentley S.D., et al., The complete genome sequence and analysis of *Corynebacterium diphtheriae* NCTC13129, *Nucleic Acids Res.* 31 (2003) 6516–6523.
- [21] Çetinkaya B., Karahan M., Atil E., Kalin R., De Baere T., Vanechoutte M., Identification of *Corynebacterium pseudotuberculosis* isolates from sheep and goats by PCR, *Vet. Microbiol.* 2359 (2002) 1–9.
- [22] Chaplin P.J., De Rose R., Boyle J.S., McWaters P., Kelly J., Tennent J.M., Lew A.M., Scheerlinck

- J.-P.Y., Targeting improves the efficacy of a DNA vaccine against *Corynebacterium pseudotuberculosis* in sheep, *Infect. Immun.* 67 (1999) 6434–6438.
- [23] Cianciotto N., Groman N., A beta-related corynebacteriophage which lacks a *tox* allele but can acquire it by recombination with phage, *Infect. Immun.* 49 (1985) 32–35.
- [24] Cianciotto N., Rappuoli R., Groman N., Detection of homology to the beta bacteriophage integration site in a wide variety of *Corynebacterium* ssp., *J. Bacteriol.* 168 (1986) 103–108.
- [25] Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al., Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence, *Nature* 393 (1998) 537–544.
- [26] Collins M.D., Goodfellow M., Minnikin D.E., Fatty acid composition of some mycolic acid-containing coryneform bacteria, *J. Gen. Microbiol.* 128 (1982) 2503–2509.
- [27] Collins M.D., Falsen E., Akervall E., Sjoden B., Alvarez A., *Corynebacterium kroppenstedtii* sp. Nov., a novel corynebacterium that does not contain mycolic acids, *Int. J. Syst. Bacteriol.* 48 (1998) 1449–1454.
- [28] Connor K.M., Quirie M.M., Baird G., Donachie W., Characterization of United Kingdom isolates of *Corynebacterium pseudotuberculosis* using pulsed-field gel electrophoresis, *J. Clin. Microbiol.* 38 (2000) 2633–2637.
- [29] Costa L.R.R., Spier S.J., Hirsh D.C., Comparative molecular characterization of *Corynebacterium pseudotuberculosis* of different origin, *Vet. Microbiol.* 62 (1998) 135–143.
- [30] Coyle M.B., Lipsky B.A., Coryneform bacteria in infectious diseases: clinical and laboratory aspects, *Clin. Microbiol. Rev.* 3 (1990) 227–246.
- [31] De Rose R., Tennent J., McWaters P., Chaplin P.J., Wood P.R., Kimpton W., Cahill R., Scheerlinck J.P., Efficacy of DNA vaccination by different routes of immunisation in sheep, *Vet. Immunol. Immunopathol.* 90 (2002) 55–63.
- [32] Dercksen D.P., ter Laak E.A., Schreuder B.E., Eradication programme for caseous lymphadenitis in goats in The Netherlands, *Vet. Rec.* 138 (1996) 237.
- [33] Dercksen D.P., Brinkhof J.M.A., Dekker-Nooren T., van Maanen K., Bode C.F., Baird G., Kamp E.M., A comparison of four serological tests for the diagnosis of caseous lymphadenitis in sheep and goats, *Vet. Microbiol.* 75 (2000) 167–175.
- [34] Egen N.B., Cuevas W., McNamara P.J., Sammons D.W., Humphreys R., Songer J.G., Purification of the phospholipase D of *Corynebacterium pseudotuberculosis* by recycling isoelectric focusing, *Am. J. Vet. Res.* 50 (1989) 1319–1322.
- [35] Fernández E.P., Vela A.I., Las Heras A., Domínguez L., Fernández-Garayzábal J.F., Moreno M.A., Antimicrobial susceptibility of corynebacteria isolated from ewe's mastitis, *Int. J. Antimicrob. Agents* 18 (2001) 571–574.
- [36] Fleischmann R.D., Alland D., Eisen J.A., Carpenter L., White O., Peterson J., et al., Whole-genome comparison of *Mycobacterium tuberculosis* clinical and laboratory strains, *J. Bacteriol.* 184 (2002) 5479–5490.
- [37] Foley J.E., Spier S.J., Mihalyi J., Drazenovich N., Leutenegger C.M., Molecular epidemiologic features of *Corynebacterium pseudotuberculosis* isolated from horses, *Am. J. Vet. Res.* 65 (2004) 1734–1737.
- [38] Fsihi H., Cole S.T., The *Mycobacterium leprae* genome: systematic sequence analysis identifies key catabolic enzymes, ATP-dependent transport systems and a novel *poIA* locus associated with genomic variability, *Mol. Microbiol.* 16 (1995) 909–919.
- [39] Funke G., Lawson P.A., Collins M.D., Heterogeneity within human-derived centers for disease control and prevention (CDC) coryneform group ANF-1-like bacteria and description of *Corynebacterium auris* sp. nov., *Int. J. Syst. Bacteriol.* 45 (1995) 735–739.
- [40] Garg D.N., Nain S.P.S., Chandiramani N.K., Isolation and characterization of *Corynebacterium ovis* from sheep and goats, *Indian Vet. J.* 62 (1985) 805–808.
- [41] Garnier T., Eiglmeier K., Camus J.C., Medina N., Mansoor H., Pryor M., et al., The complete genome sequence of *Mycobacterium bovis*, *Proc. Natl. Acad. Sci. USA* 100 (2003) 7877–7882.
- [42] Gibson C.M., Caparon M.G., Alkaline phosphatase reporter transposon for identification of genes encoding secreted proteins in gram-positive microorganisms, *Appl. Environ. Microbiol.* 68 (2002) 928–932.
- [43] Goodfellow M., Suprageneric classification of actinomycetes, in: Williams S.T. (Ed.), *Bergey's manual of systematic bacteriology*, Williams & Wilkins, Baltimore, 1989, pp. 2333–2343.
- [44] Groman N., Schiller J., Russell J., *Corynebacterium ulcerans* and *Corynebacterium pseudotuberculosis* responses to DNA probes derived from coryneophage  $\beta$  and *Corynebacterium*

- diphtheriae*, Infect. Immun. 45 (1984) 511–517.
- [45] Hall V., Collins M.D., Hutson R.A., Lawson P.A., Falsen E., Duerden B.I., *Corynebacterium atypicum* sp. nov., from a human clinical source, does not contain corynomycolic acids, Int. J. Syst. Evol. Microbiol. 53 (2003) 1065–1068.
- [46] Hard G.C., Electron microscopy examination of *Corynebacterium ovis*, J. Bacteriol. 97 (1969) 1480–1485.
- [47] Hard G.C., Examination by electron microscopy of the interaction between peritoneal phagocytes and *Corynebacterium ovis*, J. Med. Microbiol. 5 (1972) 483–491.
- [48] Hard G.C., Comparative toxic effect on the surface lipid of *Corynebacterium ovis* on peritoneal macrophages, Infect. Immun. 12 (1975) 4139–4149.
- [49] Haynes J.A., Tkalcovic J., Nisbet I.T., Production of an enzymatically inactive analog of phospholipase D from *Corynebacterium pseudotuberculosis*, Gene 119 (1992) 119–121.
- [50] Hodgson A.L., Bird P., Nisbet I.T., Cloning, nucleotide sequence, and expression in *Escherichia coli* of the phospholipase D gene from *Corynebacterium pseudotuberculosis*, J. Bacteriol. 172 (1990) 1256–1261.
- [51] Hodgson A.L.M., Krywult J., Corner L.A., Rothel J.S., Radford A.J., Rational attenuation of *Corynebacterium pseudotuberculosis*: potential cheesy gland vaccine and live delivery vehicle, Infect. Immun. 60 (1992) 2900–2905.
- [52] Hodgson A.L., Carter K., Tachedjian M., Krywult J., Corner L.A., McColl M., Cameron A., Efficacy of an ovine caseous lymphadenitis vaccine formulated using a genetically inactive form of the *Corynebacterium pseudotuberculosis* phospholipase D, Vaccine 17 (1999) 802–808.
- [53] Holt J.G., Krieg N.R., Sneath P.H.A., Staley J.T., Williams S.T., Irregular, nonsporing Gram-positive rods, in: Holt J.G., Krieg N.R., Sneath P.H.A., Staley J.T., Williams S.T. (Eds.), Bergey's manual of determinative bacteriology, Williams & Wilkins, Baltimore, 1994, p. 593.
- [54] Hou X.-G., Kawamura Y., Sultana F., Hirose K., Miyake M., Otsuka Y., Misawa S., Oguri T., Yamamoto H., Ezaki T., Genetic identification of members of the genus *Corynebacterium* at genus and species levels with 16S rDNA-targeted probes, Microbiol. Immunol. 41 (1997) 453–460.
- [55] Ikeda M., Nakagawa S., The *Corynebacterium glutamicum* genome: features and impacts on biotechnological processes, Appl. Microbiol. Biotechnol. 62 (2003) 99–109.
- [56] Ishikawa J., Yamashita A., Mikami Y., Hoshino Y., Kurita H., Hotta K., Shiba T., Hattori M., The complete genomic sequence of *Nocardia farcinica* IFM 10152, Proc. Natl. Acad. Sci. USA 101 (2004) 14925–14930.
- [57] Jolly R.D., The pathogenesis of experimental *Corynebacterium ovis* infection in mice, N. Z. Vet. J. 13 (1965) 141–147.
- [58] Jolly R.D., Some observations on surface lipids of virulent and attenuated strains of *Corynebacterium ovis*, J. Appl. Bacteriol. 29 (1966) 189–196.
- [59] Jones D., Collins M.D., Irregular, nonsporing Gram-positive rods, in: Smeath P.H.A., Mair N.S., Sharpe M.E., Holt J.G. (Eds.), Bergey's manual of systematic bacteriology, Williams & Wilkins, Baltimore, 1986, pp. 1261–1282.
- [60] Judson R., Songer J.G., *Corynebacterium pseudotuberculosis*: in vitro susceptibility to 39 antimicrobial agents, Vet. Microbiol. 27 (1991) 145–150.
- [61] Khamis A., Raoult D., La Scola B., *rpoB* gene sequencing for identification of *Corynebacterium* species, J. Clin. Microbiol. 42 (2004) 3925–3931.
- [62] Khamis A., Raoult D., La Scola B., Comparison between *rpoB* and 16S rRNA gene sequencing for molecular identification of 168 clinical isolates of *Corynebacterium*, J. Clin. Microbiol. 43 (2005) 1934–1936.
- [63] Kim B.J., Lee S.H., Lyu M.A., Kim S.J., Bai G.H., Kim S.J., Chae G.T., Kim E.C., Cha C.Y., Kook Y.H., Identification of Mycobacterial species by comparative sequence analysis of the RNA polymerase gene (*rpoB*), J. Clin. Microbiol. 37 (1999) 1714–1720.
- [64] Kumar S., Tamura K., Nei M., MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment, Brief. Bioinform. 5 (2004) 150–163.
- [65] Lipsky B.A., Goldberger A.C., Tompkins L.S., Plorde J.J., Infections caused by non-diphtheria corynebacteria, Rev. Infect. Dis. 4 (1982) 1220–1235.
- [66] Literák I., Horváthová A., Jahnová M., Rychlík I., Skalka B., Phenotype and genotype of the Slovak and Czech *Corynebacterium pseudotuberculosis* strains isolated from sheep and goats, Small Rumin. Res. 32 (1999) 107–111.
- [67] Liu D.T., Chan W.M., Fan D.S., Lam D.S., An infected hydrogel buckle with *Corynebacterium pseudotuberculosis*, Br. J. Ophthalmol. 89 (2005) 245–246.
- [68] McNamara P.J., Bradley G.A., Songer J.G., Targeted mutagenesis of the phospholipase D

- results in decreased virulence of *Corynebacterium pseudotuberculosis*, Mol. Microbiol. 12 (1994) 921–930.
- [69] McNamara P.J., Cuevas W.A., Songer J.G., Toxic phospholipases D of *Corynebacterium pseudotuberculosis*, *C. ulcerans* and *Arcanobacterium haemolyticum*: cloning and sequence homology, Gene 156 (1995) 113–118.
- [70] Menzies P.I., Muckle C.A., The use of a microagglutination assay for the detection of antibodies to *Corynebacterium pseudotuberculosis* in naturally infected sheep and goat flocks, Can. J. Vet. Res. 53 (1989) 313–318.
- [71] Menzies P.I., Hwang T.-I., Prescott J.F., Comparison of an interferon-gamma to a phospholipase D enzyme-linked immunosorbent assay for diagnosis of *Corynebacterium pseudotuberculosis* infection in experimentally infected goats, Vet. Microbiol. 100 (2004) 129–137.
- [72] Merchant I.A., Packer R.A., The Genus *Corynebacterium*, in: Merchant I.A., Packer R.A. (Eds.), Veterinary bacteriology and virology, The Iowa State University Press, Iowa, 1967, pp. 425–440.
- [73] Mills A.E., Mitchell R.D., Lim E.K., *Corynebacterium pseudotuberculosis* is a cause of human necrotising granulomatous lymphadenitis, Pathology 29 (1997) 231–233.
- [74] Mollet C., Drancourt M., Raoult D., *rpoB* sequence analysis as a novel basis for bacterial identification, Mol. Microbiol. 26 (1997) 1005–1011.
- [75] Moore R.J., Rothel L., Krywult J., Radford A.J., Lund K., Hodgson A.L., Foreign gene expression in *C. pseudotuberculosis*: development of a live vaccine vector, Vaccine 18 (2000) 487–497.
- [76] Moore R.J., Stewart D.J., Lund K., Hodgson A.L., Vaccination against ovine footrot using a live bacterial vector to deliver basic protease antigen, FEMS Microbiol. Lett. 194 (2001) 193–196.
- [77] Muckle C.A., Gyles C.L., Characterization of strains of *Corynebacterium pseudotuberculosis*, Can. J. Comp. Med. 46 (1982) 206–208.
- [78] Muckle C.A., Gyles C.L., Relation of lipid content and exotoxin production to virulence of *Corynebacterium pseudotuberculosis* in mice, Am. J. Vet. Res. 44 (1983) 1149–1153.
- [79] Muckle C.A., Menzies P.I., Li Y., Hwang Y.T., van Wesenbeeck M., Analysis of the immunodominant antigens of *Corynebacterium pseudotuberculosis*, Vet. Microbiol. 30 (1992) 47–58.
- [80] Navas J., Genetic tools in pathogenic nocardioform actinomycetes, Microbiologia 12 (1996) 297–304.
- [81] Nishio Y., Nakamura Y., Kawarabayasi Y., Usuda Y., Kimura E., Sugimoto S., Matsui K., Yamagishi A., Kikuchi H., Ikeo K., Gojobori T., Comparative complete genome sequence analysis of the amino acid replacements responsible for the thermostability of *Corynebacterium efficiens*, Genome Res. 13 (2003) 1572–1579.
- [82] Olson M.E., Ceri H., Morck D.W., Buret A.G., Read R.R., Biofilm bacteria: formation and comparative susceptibility to antibiotics, Can. J. Vet. Res. 66 (2002) 86–92.
- [83] Paton M.W., Rose I.R., Hart R.A., Sutherland S.S., Mercy A.R., Ellis T.M., Dhaliwal J.A., New infection with *Corynebacterium pseudotuberculosis* reduces wool production, Aust. Vet. J. 71 (1994) 47–49.
- [84] Paton M.W., Sutherland S.S., Rose I.R., Hart R.A., Mercy A.R., Ellis T.M., The spread of *Corynebacterium pseudotuberculosis* infection to unvaccinated and vaccinated sheep, Aust. Vet. J. 72 (1995) 266–269.
- [85] Paton M.W., Walker S.B., Rose I.R., Watt G.F., Prevalence of caseous lymphadenitis and usage of caseous lymphadenitis vaccines in sheep flocks, Aust. Vet. J. 81 (2003) 91–95.
- [86] Paule B.J.A., Azevedo V., Regis L.F., Carminati R., Bahia C.R., Vale V.L.C., Moura-Costa L.F., Freire S.M., Nascimento I., Schaer R., Goes A.M., Meyer R., Experimental *Corynebacterium pseudotuberculosis* primary infection in goats: kinetics of IgG and interferon- $\gamma$  production, IgG avidity and antigen recognition by Western blotting, Vet. Immunol. Immunopathol. 96 (2003) 129–139.
- [87] Paule B.J.A., Meyer R., Moura-Costa L.F., Bahia C.R., Carminati R., Regis L.F., Vale V.L.C., Freire S.M., Nascimento I., Schaer R., Azevedo V., Three-phase partitioning as an efficient method for extraction/concentration of immunoreactive excreted-secreted proteins of *Corynebacterium pseudotuberculosis*, Protein Expr. Purif. 34 (2004) 311–166.
- [88] Paustian M.L., Amonsin A., Kapur V., Bannantine J.P., Characterization of novel coding sequences specific to *Mycobacterium avium* subsp. *paratuberculosis*: implications for diagnosis of Johne's Disease, J. Clin. Microbiol. 42 (2004) 2675–2681.
- [89] Peel M.M., Palmer G.G., Stacpoole A.M., Kerr T.G., Human lymphadenitis due to *Corynebacterium pseudotuberculosis*: report of ten cases from Australia and review, Clin. Infect. Dis. 24 (1997) 185–191.

- [90] Pepin M., Boisrame A., Marly J., *Corynebacterium pseudotuberculosis*: biochemical properties, production of toxin and virulence of ovine and caprine strains, *Ann. Rech. Vet.* 20 (1989) 111–115.
- [91] Piontkowski M.D., Shivvers D.W., Evaluation of a commercially available vaccine against *Corynebacterium pseudotuberculosis* for use in sheep, *J. Am. Vet. Med. Assoc.* 212 (1998) 1765–1768.
- [92] Pogson C.A., Simmons C.P., Strugnell R.A., Hodgson A.L.M., Cloning and manipulation of the *Corynebacterium pseudotuberculosis recA* gene for live vaccine vector development, *FEMS Microbiol. Lett.* 142 (1996) 139–145.
- [93] Prescott J.F., Menzies P.I., Hwang Y.T., An interferon-gamma assay for diagnosis of *Corynebacterium pseudotuberculosis* infection in adult sheep from a research flock, *Vet. Microbiol.* 88 (2002) 287–297.
- [94] Puech V., Chami M., Lemassu A., Lanéelle M.-A., Schiffler B., Gounon P., Bayan N., Benz R., Daffé M., Structure of the cell envelope of corynebacteria: importance of the non covalently bound lipids in the formation of the cell wall permeability barrier and fracture plane, *Microbiology* 147 (2001) 1365–1382.
- [95] Riegel P., Ruimy R., de Briel D., Prévost G., Jehl F., Christen R., Monteil H., Taxonomy of *Corynebacterium diphtheriae* and related taxa, with recognition of *Corynebacterium ulcerans* sp. nov. nom. rev., *FEMS Microbiol. Lett.* 126 (1995) 271–276.
- [96] Saitou N., Nei M., The neighbor-joining method: a new method for reconstructing phylogenetic trees, *Mol. Biol. Evol.* 4 (1987) 406–425.
- [97] Selim A.S., Oedematous skin disease of buffalo in Egypt, *J. Vet. Med. B Infect. Dis. Vet. Public Health* 48 (2001) 241–258.
- [98] Simmons C.P., Hodgson A.L.M., Strugnell R.A., Attenuation and vaccine potential of *aroQ* mutants of *Corynebacterium pseudotuberculosis*, *Infect. Immun.* 65 (1997) 3048–3056.
- [99] Simmons C.P., Dunstan S.J., Tachedjian M., Krywult J., Hodgson A.L., Strugnell R.A., Vaccine potential of attenuated mutants of *Corynebacterium pseudotuberculosis*, *Infect. Immun.* 66 (1998) 474–479.
- [100] Songer J.G., Beckenbach K., Marshall M.M., Olson G.B., Kelley L., Biochemical and genetic characterization of *Corynebacterium pseudotuberculosis*, *Am. J. Vet. Res.* 49 (1988) 223–226.
- [101] Songer J.G., Libby S.J., Iandolo J.J., Cuevas W.A., Cloning and expression of the phospholipase D gene from *Corynebacterium pseudotuberculosis* in *Escherichia coli*, *Infect. Immun.* 58 (1990) 131–136.
- [102] Songer J.G., Bacterial phospholipases and their role in virulence, *Trends Microbiol.* 5 (1997) 156–160.
- [103] Stanford K., Brogden K.A., McClelland L.A., Kozub G.C., Audibert F., The incidence of caseous lymphadenitis in Alberta sheep and assessment of impact by vaccination with commercial and experimental vaccines, *Can. J. Vet. Res.* 62 (1998) 38–43.
- [104] Sutherland S.S., Ellis T.M., Mercy A.R., Paton M., Middleton H., Evaluation of an enzyme-linked immunosorbent assay for the detection of *Corynebacterium pseudotuberculosis* infection in sheep, *Aust. Vet. J.* 64 (1987) 263–266.
- [105] Sutherland S.S., Hart R.A., Buller N.B., Genetic differences between nitrate-negative and nitrate-positive *C. pseudotuberculosis* strains using restriction fragment length polymorphisms, *Vet. Microbiol.* 49 (1996) 1–9.
- [106] Tachedjian M., Krywult J., Moore R.J., Hodgson A.L., Caseous lymphadenitis vaccine development: site-specific inactivation of the *Corynebacterium pseudotuberculosis* phospholipase D gene, *Vaccine* 13 (1995) 1785–1792.
- [107] Takahashi T., Mori Y., Kobayashi H., Ochi M., Kikuchi N., Hiramune T., Phylogenetic positions and assignments of swine and ovine corynebacteria isolated based on the 16S rDNA sequence, *Microbiol. Immunol.* 41 (1997) 649–655.
- [108] Tambourgi D.V., Da Silva M.S., Billington S.J., Gonçalves De Andrade R.M., Magnoli F.C., Songer J.G., Van Den Berg C.W., Mechanism of induction of complement susceptibility of erythrocytes by spider and bacterial sphingomyelinases, *Immunol.* 107 (2002) 93–101.
- [109] Tashjian J.J., Campbell S.G., Interaction between caprine macrophages and *Corynebacterium pseudotuberculosis*: an electron microscopy study, *Am. J. Vet. Res.* 44 (1983) 690–693.
- [110] ter Laak E.A., Bosch J., Bijl G.C., Schreuder B.E., Double-antibody sandwich enzyme-linked immunosorbent assay and immunoblot analysis used for control of caseous lymphadenitis in goats and sheep, *Am. J. Vet. Res.* 53 (1992) 1125–1132.
- [111] Vaneechoutte M., Riegel P., de Briel D., Monteil H., Verschraegen G., De Rouck A., Claeys G., Evaluation of applicability of amplified rDNA-restriction analysis (ARDRA) to identification of species of the genus

- Corynebacterium*, Res. Microbiol. 146 (1995) 633–641.
- [112] van Meeteren L.A., Frederiks F., Giepmans B.N.G., Pedrosa M.F.F., Billington S.J., Jost B.H., Tambourgi D.V., Moolenaar W.H., Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine, J. Biol. Chem 279 (2004) 10833–10836.
- [113] Walker J., Jackson H.J., Eggleton D.G., Meeusen E.N.T., Wilson M.J., Brandon M.R., Identification of a novel antigen from *Corynebacterium pseudotuberculosis* that protects sheep against caseous lymphadenitis, Infect. Immun. 62 (1994) 2562–2567.
- [114] Williamson L.H., Caseous lymphadenitis in small ruminants, Vet. Clin. North Am. Food Anim. Pract. 17 (2001) 359–371.
- [115] Wilson M.J., Brandon M.R., Walker J., Molecular and biochemical characterization of a protective 40-kDa antigen from *Corynebacterium pseudotuberculosis*, Infect. Immun. 63 (1995) 206–211.
- [116] Yeruham I., Braverman Y., Shpigel N.Y., Chizov-Ginzburg A., Saran A., Winkler M., Mastitis in dairy cattle caused by *Corynebacterium pseudotuberculosis* and the feasibility of transmission by houseflies, Vet. Q. 18 (1996) 87–89.
- [117] Yeruham I., Friedman S., Perl S., Elad D., Berkovich Y., Kalgard Y., A herd level analysis of a *Corynebacterium pseudotuberculosis* outbreak in a dairy cattle herd, Vet. Dermatol. 15 (2004) 315–320.
- [118] Zaki M.M., The application of a new technique for diagnosing *Corynebacterium ovis* infection, Res. Vet. Sci. 9 (1968) 489–493.